Management of proctitis in ulcerative colitis and the place of biological therapies.
Biological therapy
clinical trial
proctitis
refractory
therapy
ulcerative colitis
Journal
Expert opinion on biological therapy
ISSN: 1744-7682
Titre abrégé: Expert Opin Biol Ther
Pays: England
ID NLM: 101125414
Informations de publication
Date de publication:
14 Jun 2024
14 Jun 2024
Historique:
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
14
6
2024
Statut:
aheadofprint
Résumé
Approximately 20-30% of patients with ulcerative colitis (UC) may present with isolated proctitis. Ulcerative proctitis (UP) is a challenging condition to manage due to its significant burden in terms of disabling symptoms. PubMed was searched up to March 2024 to identify relevant studies on UP. A comprehensive summary and critical appraisal of the available data on UP is provided, highlighting emerging treatments and areas for future research. Patients with UP are often undertreated and the disease burden is often underestimated in clinical practice. Treat-to-target management algorithms can be applied to UP, aiming for clinical remission in the short term, and endoscopic remission and maintenance of remission in the long term. During their disease, approximately one third of UP patients require advanced therapies. Escalation to biologic therapy is required for refractory or steroid dependent UP. For optimal patient care and management of UP, it is necessary to include these patients in future randomized clinical trials.
Identifiants
pubmed: 38874980
doi: 10.1080/14712598.2024.2369189
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM